Literature DB >> 6017531

Allopurinol.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 6017531      PMCID: PMC1840849     

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  8 in total

1.  4-HYDROXYPYRAZOLO (3,4-D) PYRIMIDINE (HPP) IN THE TREATMENT OF GOUT: PRELIMINARY OBSERVATIONS.

Authors:  A P HALL; V P HOLLOWAY; J T SCOTT
Journal:  Ann Rheum Dis       Date:  1964-11       Impact factor: 19.103

2.  Allopurinol in the treatment of gout.

Authors:  R W Rundles; E N Metz; H R Silberman
Journal:  Ann Intern Med       Date:  1966-02       Impact factor: 25.391

3.  Xanthine oxidase inhibitors in the management of gout.

Authors:  J B Wyngaarden
Journal:  Arthritis Rheum       Date:  1965-10

4.  Haemosiderosis associated with xanthine oxidase inhibition.

Authors:  L W Powell; B T Emmerson
Journal:  Lancet       Date:  1966-01-29       Impact factor: 79.321

5.  Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease.

Authors:  R C DeConti; P Calabresi
Journal:  N Engl J Med       Date:  1966-03-03       Impact factor: 91.245

6.  Allopurinal and acute uric acid nephropathy.

Authors:  R W Watts; P J Watkins; J Q Matthias; D A Gibbs
Journal:  Br Med J       Date:  1966-01-22

7.  Allopurinol in treatment of gout.

Authors:  J T Scott; A P Hall; R Grahame
Journal:  Br Med J       Date:  1966-08-06

8.  EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT.

Authors:  T F YUE; A B GUTMAN
Journal:  Am J Med       Date:  1964-12       Impact factor: 4.965

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.